Related Experiment Videos
Predicting patients' exposure to cyclosporin
A Johnston1, J M Kovarik, E A Mueller
1Clinical Pharmacology, St Bartholomew's Hospital, London, UK.
Summary
A simplified blood sampling strategy accurately predicts cyclosporine area-under-curve (AUC) in renal transplant patients using the Neoral formulation. Two samples, taken 2 and 8 hours post-dose, can reliably estimate cyclosporine AUC, potentially simplifying therapeutic drug monitoring.
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Nephrology and Transplant Medicine
- Clinical Pharmacy
Background:
- Neoral, a new cyclosporine formulation, reduces pharmacokinetic variability.
- Accurate monitoring of cyclosporine's area-under-curve (AUC) is crucial for transplant patients.
- Limited sampling strategies may simplify AUC measurement.
Purpose of the Study:
- To determine the optimal timing for limited blood sampling to predict cyclosporine AUC.
- To validate a limited sampling strategy for Neoral in stable renal transplant recipients.
Main Methods:
- Utilized best subset regression analysis on cyclosporine concentration data from 10 stable renal transplant patients.
- Identified key time points for blood sample collection to predict AUC.
- Validated the predictive model using data from 36 additional patients over multiple time points.
Main Results:
- Two blood samples, collected at 2 and 8 hours post-dose, explained 97% of the variance in AUC.
- The derived regression equation (AUC = 1.96 x [2 h] + 11.5 x [8 h] + 355.2) demonstrated low prediction errors (mean 1.7%, 3.3%, 0.4%).
- The findings suggest feasibility of AUC monitoring using a single blood sample in clinical practice.
Conclusions:
- A limited sampling strategy with two time points (2 and 8 hours post-dose) provides accurate prediction of cyclosporine AUC for Neoral.
- This simplified approach can aid in therapeutic drug monitoring for renal transplant patients.
- Further investigation into single-sample AUC monitoring may be warranted.